ABBV eyes a 2025 rebound as Skyrizi and Rinvoq drive growth beyond Humira, with oncology and neuroscience adding momentum.
If you have been following AbbVie (ABBV), the company’s latest move might sway your decision on whether to stick with or jump ...
Anticipated late-stage results in the skin disease hidradenitis suppurativa were described by analysts as “disappointing” and ...
Boring dividend growers that send checks every quarter while everyone else chases the next shiny object. The math is ...
4don MSN
Where Will AbbVie Be in 5 Years?
There's no doubt in my mind that AbbVie will remain a Dividend King five years from now. This elite group consists only of ...
6don MSNOpinion
Op-Ed: PBMs, not flashy headlines, keep drug prices low
On Monday, a state-funded committee in Louisiana gave Mark Cuban’s Cost Plus Drug Company a taxpayer-funded microphone to ...
AbbVie combines strong earnings, rising dividends, and growth from Skyrizi and Rinvoq, making it a top dividend pick. Read ...
MedPage Today on MSN
Sugary Drinks and Colon Cancer; Reflux Device to Exit Markets; Latino Liver Disease
Experts reviewed the use of targeted therapy in cholangiocarcinoma, along with efforts to reduce the burden of ...
These three dividend stocks offer different paths to steady income and long-term wealth creation. AbbVie provides growth with ...
So, dividend seekers must carefully select which stocks to add to their portfolios if they wish to maintain steadily rising ...
For two decades, immunology was the golden child of biopharma. Blockbusters like Humira (adalimumab), Enbrel (etanercept) and Remicade (infliximab) dominated the sales charts and funded pipelines ...
Bank of America Global Healthcare Conference 2025 September 23, 2025 4:50 AM EDTCompany ParticipantsPaul Hudson - CEO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback